Haleon Revenue Rises, Helped by Sparkling Toothpaste Sales
By Aimee Look
Haleon booked a rise in organic revenue for the second quarter, when more consumers reached for oral-health products like Sensodyne toothpaste.
The London-listed consumer healthcare company booked a 3.1% rise in organic revenue for the second quarter of the year, in line with company-compiled expectations.
Haleon's Sensodyne products posted double-digit growth, it said, while revenue for its oral health segment in general grew 6.2% organically on year for the quarter.
Also home to brands like Panadol and Advil medicine, Haleon reported revenue of 5.6 billion pounds ($7.49 billion) for the half year, compared with 5.48 billion pounds in the year-prior period.
Adjusted operating profit--which strips out exceptional and other one-off items--in the first six months grew 8.2% on year to 1.36 billion pounds.
Haleon backed its outlook for the full year, still expecting organic revenue growth between 3%-5%.
Write to Aimee Look at aimee.look@wsj.com
(END) Dow Jones Newswires
July 30, 2026 02:47 ET (06:47 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States